IER3抗体;IER3 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13174(IER3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The Immediate Early Response 3 (IER3) protein, also known as IEX-1. is a stress-inducible regulatory factor encoded by the IER3 gene. It plays critical roles in cell proliferation, apoptosis, and adaptive responses to cellular stress. IER3 interacts with key signaling pathways, including the PI3K/AKT and MAPK cascades, and modulates NF-κB activity, influencing inflammation, immunity, and cancer progression. Its expression is tightly regulated by growth factors, cytokines, DNA damage, and chemotherapeutic agents, reflecting its dual pro-survival or pro-apoptotic functions depending on cellular context.

IER3 antibodies are essential tools for studying its expression, localization, and interactions in various diseases. In cancer research, IER3 antibodies help assess its dysregulation in tumors, such as breast, colorectal, and hepatocellular carcinomas, where it may act as an oncogene or tumor suppressor. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to explore IER3’s role in chemotherapy resistance, immune evasion, or metastasis.

Recent studies highlight IER3’s potential as a biomarker for disease prognosis or therapeutic targeting. For example, elevated IER3 levels correlate with poor outcomes in certain cancers, while its downregulation links to autoimmune disorders. Commercial IER3 antibodies are typically validated for specificity across human and mouse models, aiding translational research. However, variable post-translational modifications and tissue-specific isoforms necessitate careful antibody selection to ensure experimental accuracy.